Abstract
Andreas Herrmann
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1111/j.1476-5381.2011.01729.x
10.1111/j.1476-5381.2011.01729.x
10.1007/s10741-008-9130-x
10.1007/s10741-008-9130-x
Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia
10.1523/jneurosci.1635-10.2010 · 2010
10.1242/jcs.01096
10.1242/jcs.01096
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists
10.1007/s11934-003-0027-x · 2003
10.1038/bjp.2008.307
10.1038/bjp.2008.307
Evaluation of a new bipyridine inotropic agent–milrinone–in patients with severe congestive heart failure
10.1056/nejm198309293091302 · 1983
Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function
10.1038/ijir.2008.4 · 2008
Milrinone: basic and clinical pharmacology and acute and chronic management
10.1016/s0002-9629(15)41723-9 · 1996
10.1021/acs.jmedchem.5b01813
10.1021/acs.jmedchem.5b01813
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity
10.1021/ja404449g · 2013
10.1016/j.neuropharm.2004.07.040
10.1016/j.neuropharm.2004.07.040
10.1124/mol.115.099671
10.1124/mol.115.099671
10.1016/j.drudis.2013.02.007
10.1016/j.drudis.2013.02.007
10.1021/ja202726y
10.1021/ja202726y
Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity
10.1021/bi049868i · 2004
Discovery of triazines as potent, selective and orally active PDE4 inhibitors
10.1016/j.bmcl.2013.05.099 · 2013
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development
10.1074/jbc.m512527200 · 2006
10.1073/pnas.0401120101
10.1073/pnas.0401120101
10.1073/pnas.0700279104
10.1073/pnas.0700279104
10.1006/jmbi.1993.1626
10.1006/jmbi.1993.1626
10.1038/nmeth.3213
10.1038/nmeth.3213
10.1016/0263-7855(96)00018-5
10.1016/0263-7855(96)00018-5
10.1021/ct300400x
10.1021/ct300400x
10.1063/1.445869
10.1063/1.445869
10.1002/jcc.21816
10.1002/jcc.21816
10.1063/1.467468
10.1063/1.467468
10.1002/jcc.20289
10.1002/jcc.20289
10.1063/1.464397
10.1063/1.464397
10.1063/1.470117
10.1063/1.470117
10.1016/0021-9991(77)90098-5
10.1016/0021-9991(77)90098-5
10.1063/1.448118
10.1063/1.448118
10.1103/physreva.31.1695
10.1103/physreva.31.1695
10.1063/1.447334
10.1063/1.447334
10.1093/nar/gki524
10.1093/nar/gki524
A semiempirical free energy force field with charge-based desolvation
10.1002/jcc.20634 · 2007
10.1002/jcc.21256
10.1002/jcc.21256
Unresolved referenced work
1976
Unresolved referenced work
2015
Unresolved referenced work
2017
10.1016/j.drudis.2016.11.001
10.1016/j.drudis.2016.11.001 · doi-reference
10.1021/jacs.6b11467
10.1021/jacs.6b11467 · doi-reference
10.1021/jm2010332
10.1021/jm2010332 · doi-reference
10.1126/science.1095920
10.1126/science.1095920 · doi-reference
Strategies for the discovery of target-specific or isoform-selective modulators
10.1021/acs.jmedchem.5b00229 · doi-reference
10.1073/pnas.44.2.98
10.1073/pnas.44.2.98 · doi-reference
Design strategies to address kinetics of drug binding and residence time
10.1016/j.bmcl.2015.02.027 · doi-reference
10.1038/nrd2082
10.1038/nrd2082 · doi-reference
10.1038/nature06522
10.1038/nature06522 · doi-reference
10.1110/ps.8.6.1181
10.1110/ps.8.6.1181 · doi-reference
10.1016/j.str.2004.10.004
10.1016/j.str.2004.10.004 · doi-reference